Search Results | Diabetes Care | American Diabetes Association

1-20 of 195

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Comment on Serés-Noriega et al. Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk. Diabetes Care 2022;45:2412–2421

José-Miguel González-Clemente, Gemma Llauradó, Albert Cano, Olga Giménez-Palop, Lara Albert, Joan Vendrell

Diabetes Care 2023;46(3):e85–e86

DOI: https://doi.org/10.2337/dc22-2344

Published: 22 February 2023

View article

Journal Articles

Response to Comment on Serés-Noriega et al. Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk. Diabetes Care 2022;45:2412–2421

Tonet Serés-Noriega, Laura Boswell, Verónica Perea, Antonio J. Amor

Diabetes Care 2023;46(3):e87–e88

DOI: https://doi.org/10.2337/dci22-0061

Published: 22 February 2023

View article

Journal Articles

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023

Diabetes Care 2023;46(Supplement_1):S158–S190

DOI: https://doi.org/10.2337/dc23-S010

Published: 12 December 2022

View article

Journal Articles

Cardiovascular Outcomes in Patients With Both Diabetes and Phenotypic Familial Hypercholesterolemia: A Nationwide Register-Based Cohort Study

Jonas Brinck, Emil Hagström, Jonatan Nåtman, Stefan Franzén, Katarina Eeg-Olofsson, David Nathanson, Björn Eliasson

Diabetes Care 2022;45(12):3040–3049

DOI: https://doi.org/10.2337/dc22-1025

Published: 01 December 2022

View article

Journal Articles

Comment on Yang et al. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease. Diabetes Care 2022;45:1184–1192

Cheng-Hsien Hung, Fu-Shun Yen, James Cheng-Chung Wei

Diabetes Care 2022;45(12):e181

DOI: https://doi.org/10.2337/dc22-0701

Published: 01 December 2022

View article

Journal Articles

Response to Comment on Yang et al. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease. Diabetes Care 2022;45:1184–1192

Yi-Sun Yang, Kai-Chieh Hu, Chia-Hung Kao

Diabetes Care 2022;45(12):e182–e183

DOI: https://doi.org/10.2337/dci22-0021

Published: 01 December 2022

View article

Journal Articles

Sleep Duration and Risks of Incident Cardiovascular Disease and Mortality Among People With Type 2 Diabetes

Han Han, Ying Wang, Tongtong Li, Chengwu Feng, Catherine Kaliszewski, Yang Su, Yinfan Wu, Jian Zhou, Liang Wang, Geng Zong

Diabetes Care 2023;46(1):101–110

DOI: https://doi.org/10.2337/dc22-1127

Published: 16 November 2022

View article

Journal Articles

Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure

Sara J. Cromer, Julie C. Lauffenburger, Raisa Levin, Elisabetta Patorno

Diabetes Care 2023;46(1):65–74

DOI: https://doi.org/10.2337/dc22-0383

Published: 16 November 2022

View article

Journal Articles

Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease

Julio A. Lamprea-Montealegre, Erin Madden, Sri Lekha Tummalapalli, Chi D. Chu, Carmen A. Peralta, Yuxian Du, Rakesh Singh, Sheldon X. Kong, Delphine S. Tuot, Michael G. Shlipak, Michelle M. Estrella

Diabetes Care 2022;45(12):2900–2906

DOI: https://doi.org/10.2337/dc22-0614

Published: 23 September 2022

View article

Journal Articles

Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis

Giulia Ferrannini, Linda G. Mellbin, Faith Kirabo, Chinthanie Ramasundarahettige, Hertzel C. Gerstein, Lars Rydén

Diabetes Care 2022;45(10):e146–e147

DOI: https://doi.org/10.2337/dc22-0903

Published: 30 August 2022

View article

Journal Articles

Associations of New-Onset Atrial Fibrillation With Risks of Cardiovascular Disease, Chronic Kidney Disease, and Mortality Among Patients With Type 2 Diabetes

Tingting Geng, Yi Wang, Qi Lu, Yan-Bo Zhang, Jun-Xiang Chen, Yan-Feng Zhou, Zhenzhen Wan, Kunquan Guo, Kun Yang, Liegang Liu, Gang Liu, An Pan

Diabetes Care 2022;45(10):2422–2429

DOI: https://doi.org/10.2337/dc22-0717

Published: 19 August 2022

View article

Journal Articles

Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk

Tonet Serés-Noriega, Marga Giménez, Verónica Perea, Laura Boswell, Clara Viñals, Jesús Blanco, Irene Vinagre, Adriana Pané, Enric Esmatjes, Ignacio Conget, Antonio J. Amor

Diabetes Care 2022;45(10):2412–2421

DOI: https://doi.org/10.2337/dc22-0118

Published: 09 August 2022

View article

Journal Articles

National Trends in the Achievement of Recommended Strategies for Stroke Prevention in U.S. Adults With Type 2 Diabetes, 2001–2018

Shihchen Kuo, Chun-Ting Yang, William H. Herman, Lynda D. Lisabeth, Wen Ye

Diabetes Care 2022;45(9):2003–2011

DOI: https://doi.org/10.2337/dc21-2283

Published: 14 July 2022

View article

Journal Articles

Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes

Kamlesh Khunti, Vanita R. Aroda

Diabetes Care 2022;45(4):766–768

DOI: https://doi.org/10.2337/dci21-0064

Published: 29 March 2022

View article

Journal Articles

GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease

Yi-Sun Yang, Hsin-Hung Chen, Chien-Ning Huang, Chung Y. Hsu, Kai-Chieh Hu, Chia-Hung Kao

Diabetes Care 2022;45(5):1184–1192

DOI: https://doi.org/10.2337/dc21-1993

Published: 11 March 2022

View article

Journal Articles

Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes

Evangelos K. Oikonomou, Marc A. Suchard, Darren K. McGuire, Rohan Khera

Diabetes Care 2022;45(4):965–974

DOI: https://doi.org/10.2337/dc21-1765

Published: 04 February 2022

View article

Journal Articles

Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes

Hui Shao, Piaopiao Li, Jingchuan Guo, Vivian Fonseca, Lizheng Shi, Ping Zhang

Diabetes Care 2022;45(2):e32–e33

DOI: https://doi.org/10.2337/dc21-1800

Published: 17 January 2022

View article

Journal Articles

Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs

Dhruv Mahtta, David J. Ramsey, Michelle T. Lee, Liang Chen, Mahmoud Al Rifai, Julia M. Akeroyd, Elizabeth M. Vaughan, Michael E. Matheny, Karla Rodrigues do Espirito Santo, Sankar D. Navaneethan, Carl J. Lavie, Yochai Birnbaum, Christie M. Ballantyne, Laura A. Petersen, Salim S. Virani

Diabetes Care 2022;45(2):372–380

DOI: https://doi.org/10.2337/dc21-1815

Published: 17 January 2022

View article

Journal Articles

Association of Baseline HbA_1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz

Diabetes Care 2022;45(4):938–946

DOI: https://doi.org/10.2337/dc21-1744

Published: 11 January 2022

View article

Journal Articles

Cost-Related Medication Nonadherence in Adults With Diabetes in the United States: The National Health Interview Survey 2013–2018

Mohamad B. Taha, Javier Valero-Elizondo, Tamer Yahya, César Caraballo, Rohan Khera, Kershaw V. Patel, Hyeon Ju R. Ali, Garima Sharma, Elias Mossialos, Miguel Cainzos-Achirica, Khurram Nasir

Diabetes Care 2022;45(3):594–603

DOI: https://doi.org/10.2337/dc21-1757

Published: 11 January 2022

View article

2 3 4 5

NARROW

Comment on Serés-Noriega et al. Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk. Diabetes Care 2022;45:2412–2421

Response to Comment on Serés-Noriega et al. Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk. Diabetes Care 2022;45:2412–2421

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023

Cardiovascular Outcomes in Patients With Both Diabetes and Phenotypic Familial Hypercholesterolemia: A Nationwide Register-Based Cohort Study

Comment on Yang et al. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease. Diabetes Care 2022;45:1184–1192

Response to Comment on Yang et al. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease. Diabetes Care 2022;45:1184–1192

Sleep Duration and Risks of Incident Cardiovascular Disease and Mortality Among People With Type 2 Diabetes

Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure

Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease

Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis

Associations of New-Onset Atrial Fibrillation With Risks of Cardiovascular Disease, Chronic Kidney Disease, and Mortality Among Patients With Type 2 Diabetes

Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk

National Trends in the Achievement of Recommended Strategies for Stroke Prevention in U.S. Adults With Type 2 Diabetes, 2001–2018

Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes

GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease

Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes

Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes

Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs

Association of Baseline HbA_1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Cost-Related Medication Nonadherence in Adults With Diabetes in the United States: The National Health Interview Survey 2013–2018

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only